Stock Movers: Novo Nordisk, United Health Group, Royal Caribbean
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
S&P/TSX composite index dips while U.S. markets mixed
TORONTO — Canada's main stock index was down in late-morning trading Thursday amid a flurry of earnings and economic data while U.S. markets were mixed. The S&P/TSX composite index was down 61.75 points at 27,308.21 as energy, telecom and financials trended lower. In New York, the Dow Jones industrial average was down 105.08 points at 44,356.20. The S&P 500 index was up 15.47 points at 6,378.37, while the Nasdaq composite was up 119.72 points at 21,249.40. The Canadian dollar traded for 72.24 cents US compared with 72.41 cents US on Wednesday as Statistics Canada data showed the economy shrank in May but growth could hold flat for the quarter overall. The September crude oil contract was down US$1.18 at US$68.82 per barrel. The December gold contract was down US$5.30 at US$3,347.50 an ounce. This report by The Canadian Press was first published July 31, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28 minutes ago
- Business Wire
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. ('Hims') and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' On this news, Novo Nordisk's stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors. Then, on July 29, 2025, Novo Nordisk cut its previously issued guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Novo Nordisk should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
CNBC
29 minutes ago
- CNBC
An options trade that bets on consumer stocks rebounding — while hedging risk
Seven months into the year, the total return for the S & P 500 is roughly 9%. The benchmark fell nearly 19% peak to trough into the post-liberation day lows, and has rallied 27% since. Given the U.S. economy's heavy reliance on consumer activity, which accounts for approximately 70% of gross domestic product, it's notable that the discretionary sector has significantly underperformed. Whereas the S & P 500 is trading at all-time highs, the consumer discretionary sector — which fell more than 26% peak-to-trough between Dec. 17 and April 8 — has yet to recover fully. It's more than 6% below its 2024 highs. Economic data has been pretty decent. Growth has exceeded expectations. Federal deficits, aided in part by tariff-related revenue, have been slightly lower than expected. Inflation, which hit levels not seen in the United States since the late 1970s in 2022, has also been moderating in the past several months. This has prompted many, the President most notably, to insist that the Fed should cut rates. Thankfully, the nation's central bank has thus far not bowed to pressure from the administration to do so. First, lower inflation — which we're grateful for — is not the same as deflation; that is, falling prices. Consequently, the cost of living remains a struggle for many as real wages declined between the second quarter of 2021 and mid-2023. Second, inflationary policy impacts remain. That's not from the Fed necessarily, which has maintained a relatively steady and predictable policy path and allowed its balance sheet to shrink, but from the Federal government, which continues on a fiscally unsustainable path. It's not just money printing and ZIRP (zero interest rate policy) that is inflationary; massive deficit spending is too. Third, even if the Fed cuts short-term rates, the cost of borrowing for durable goods and housing is driven by the longer end of the curve. Still, consumer and business sentiment have been improving, so I would expect consumer stocks to narrow their gap of underperformance relative to the S & P 500 - hopefully because they rally and not due to a fall in other sectors! One way to make a modestly bullish bet in the consumer sector is with a call spread risk reversal in Consumer Discretionary Select SPDR Fund (XLY). Purchasing an at the money call, partially financed through the sale of an 18 delta downside put and an 18 delta upside call. In the example I'm providing below, I've selected September "regular way" expiration. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
